Medical Device Network on MSN
FDA clears Median Technologies’ lung nodule evaluation software
Median's eyonis LCS is software is reimbursable under Medicare at a rate between $601 to $700.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test ...
FDA clears 1st blood test for Alzheimer’s to help primary care clinicians assess cognitive decline without brain scans or lumbar punctures.
FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda.
The US Food and Drug Administration (FDA) has granted marketing clearance to Eyonis LCS, an artificial intelligence-powered ...
FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...
Regulatory alignment from the FDA and MD Anderson IRB supports resumption of enrollment in a U.S./European proof-of-concept ...
In a regulatory milestone, the FDA clears AuraWell’s PEMF technology as the first over-the-counter frequency therapy device ...
Life Biosciences plans to begin human clinical trials of a cellular rejuvenation therapy in optic neuropathies after ...
Byonyks has developed expertise in manufacturing APD Cyclers and Tubing sets, maintains a technical support team, and is now ...
The FDA has cleared RevealDx’s AI-powered lung nodule risk assessment software, RevealAI-Lung, according to a company press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results